Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.44 |
| ▸ | ABL1 | P00519 | 12/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.44 |
| ▸ | PRKDC | P78527 | 9/20 | 0.44 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | HCK | P08631 | 8/20 | 0.44 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | MTOR | P42345 | 8/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.44 |
| ▸ | RET | P07949 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925165 | 0.84 | SRC (0.58) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18216976 | 0.75 | SRC (0.42) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16375258 | 0.69 | RET (0.40) | KDRRET | |
| SCHEMBL15079234 | 0.69 | KDM4E (0.40) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL10261918 | 0.69 | SRC (0.66) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16375264 | 0.67 | RET (0.36) | RET | |
| SCHEMBL5147544 | 0.67 | ABL1 (0.41) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL27217868 | 0.67 | ABL1 (0.43) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14692449 | 0.67 | ABL1 (0.58) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL868687 | 0.67 | ABL1 (0.58) | SRCABL1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | SRC 12/4885ABL1 1/4885PIK3CD 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.